Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Home
Femke Ringnalda

Femke Ringnalda

PhD student

Clevers groep

Phone 088 97 27 676

Email F.C.A.Ringnalda@prinsesmaximacentrum.nl

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities
- mei 2023
- Irene, Paassen, et al
- Oncogene
Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities
- jan. 2023
- Thomas, Kluiver, et al
- bioRxiv
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment
- feb. 2022
- Christian K, Hirt, et al
- Cell genomics
EWSR1-WT1 Target Genes and Therapeutic Options Identified in a Novel DSRCT In Vitro Model
- dec. 2021
- Margit, Bleijs, et al
- Cancers 2021, 13(23), 6072
The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma
- nov. 2021
- Irena, Bočkaj, et al
- PLoS Genetics

Bekijk alle publicaties

Femke Ringnalda

Publicaties

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities

Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment

EWSR1-WT1 Target Genes and Therapeutic Options Identified in a Novel DSRCT In Vitro Model

The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma